In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.
Impressum
Pieris Pharmaceuticals GmbH
Carl-Zeiss-Ring 15a
85737 Ismaning
P.: +49 89 – 26 20 22 940
vertreten durch die Geschäftsführer:
Stephen S. Yoder
Tel.: +0049 811 124470
E-Mail: info@pieris.com
Amtsgericht München HRB 221043
Umsatzsteueridentifikationsnummer: DE813177203
